Genetic induction of a releasable pool of factor VIII in human endothelialcells

Citation
Jb. Rosenberg et al., Genetic induction of a releasable pool of factor VIII in human endothelialcells, ART THROM V, 20(12), 2000, pp. 2689-2695
Citations number
42
Categorie Soggetti
Cardiovascular & Hematology Research
Journal title
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
ISSN journal
10795642 → ACNP
Volume
20
Issue
12
Year of publication
2000
Pages
2689 - 2695
Database
ISI
SICI code
1079-5642(200012)20:12<2689:GIOARP>2.0.ZU;2-X
Abstract
Although it is known that factor VIII (FVIII) plasma levels increase rapidl y in response to a number of stimuli, the biological stimuli behind this re lease is less clear. Previously, we showed that FVIII can traffic together with von Willebrand factor (vWF) into storage granules in a pituitary tumor cell line, AtT-20; however, AtT-20 cells could not be used to address the release or functional activity of released FVIII. To investigate the regula ted secretion of stored FVIII, endothelial cells with intact agonist-stimul ated release pathways were used. Human umbilical vein endothelial cells (HU VECs) were transduced with retroviral FVIII construct [kFVIII(V)] to create a FVIII/vWF storage pool. Immunofluorescent staining of transduced cells d emonstrated FVIII in Weibel-Palade bodies. In contrast, the transduction of hFVIII(V) into HT-1080 and HepG2 cells displayed FVIII only in the cytopla sm. We studied the regulated release of both FVIII and vWF from endothelial cells after agonist-induced stimulation and demonstrated a parallel releas e of FVIII and vWF proteins. This released FVIII was functionally active. H ence, endothelial cells transduced with hFVIII(V) store FVIII together with VWF in Weibel-Palade bodies, creating a releasable storage pool of both pr oteins. Because FVIII secretion can be physiologically regulated by agonist s in culture, this may explain the pharmacological agonist-induced release of FVIII by drugs such as desmopressin in vivo and suggests vascular endoth elium as a reasonable target of gene therapy of hemophilia A.